Kaifeng Yang

Mr. Kaifeng Yang

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2023 in Metabolites
Verified
Journal Article
Open access
PDF file
KYKaifeng Yang
Kaifeng Yang
ZKZhiyu Kang
Zhiyu Kang
WGWeihua Guan
Weihua Guan
SLSahar Lotfi-Emran
Sahar Lotfi-Emran
ZMZachary Mayer
Zachary Mayer
SSSandra E. Safo
Sandra E. Safo
Metabolic disease is a significant risk factor for severe COVID-19 infection, but the contributing pathways are not yet fully elucidated. Using data from two randomized controlled trials across 13 U.S. academic centers, our goal was to characterize metabolic features that predict severe COVID-19 and define a novel baseline metabolomic signature. Individuals (n = 133) were dichotomized as having mild or moderate/severe COVID-19 disease based on the WHO ordinal scale. Blood samples were analyzed using the Biocrates platform, providing 630 targeted metabolites for analysis. Resampling techniques and machine learning models were used to determine metabolomic features associated with severe disease. Ingenuity Pathway Analysis (IPA) was used for functional enrichment analysis. To aid in clinical decision making, we created baseline metabolomics signatures of low-correlated molecules. Multivariable logistic regression models were fit to associate these signatures with severe disease on training data. A three-metabolite signature, lysophosphatidylcholine a C17:0, dihydroceramide (d18:0/24:1), and triacylglyceride (20:4_36:4), resulted in the best discrimination performance with an average test AUROC of 0.978 and F1 score of 0.942. Pathways related to amino acids were significantly enriched from the IPA analyses, and the mitogen-activated protein kinase kinase 5 (MAP2K5) was differentially activated between groups. In conclusion, metabolites related to lipid metabolism efficiently discriminated between mild vs. moderate/severe disease. SDMA and GABA demonstrated the potential to discriminate between these two groups as well. The mitogen-activated protein kinase kinase 5 (MAP2K5) regulator is differentially activated between groups, suggesting further investigation as a potential therapeutic pathway.

8 May 2025 in arXiv
Verified
Preprint
Open access
PDF file
KYKaifeng Yang
Kaifeng Yang
TCThierry Chekouo
Thierry Chekouo
SSSandra E. Safo
Sandra E. Safo
Multiple types or views of data (e.g. genetics, proteomics) measured on the same set of individuals are now popularly generated in many biomedical studies. A particular interest might be the detection of sample subgroups (e.g. subtypes of disease) characterized by specific groups of variables. Biclustering methods are well-suited for this problem since they can group samples and variables simultaneously. However, most existing biclustering methods cannot guarantee that the detected sample clusters are clinically meaningful and related to a clinical outcome because they independently identify biclusters and associate sample clusters with a clinical outcome. Additionally, these methods have been developed for continuous data when integrating data from different views and do not allow for a mixture of data distributions. We propose a new formulation of biclustering and prediction method for multi-view data from different distributions that enhances our ability to identify clinically meaningful biclusters by incorporating a clinical outcome. Sample clusters are defined based on an adaptively chosen subset of variables and their association with a clinical outcome. We use extensive simulations to showcase the effectiveness of our proposed method in comparison to existing methods. Real-world applications using lipidomics, imaging, and cognitive data on Alzheimer's disease(AD) identified biclusters with significant cognitive differences that other methods missed. The distinct lipid categories and brain regions characterizing the biclusters suggest potential new insights into pathology of AD.

18 October 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
TATaiwo Opeyemi Aremu
Taiwo Opeyemi Aremu
KYKaifeng Yang
Kaifeng Yang
HLHan Lu
Han Lu
OOOluwatosin Esther Oluwole
Oluwatosin Esther Oluwole
KAKehinde Adeyinka
Kehinde Adeyinka
(1) Background: The COVID-19 pandemic has raised concerns about the impact of underlying medical conditions on the health outcomes of people living with HIV (PLWH). This study aimed to assess how pre-existing chronic medical conditions affect the health outcomes of PLWH infected with COVID-19. (2) Methods: A retrospective study using data from the Minnesota Fairview network (January 1, 2020 - December 31, 2022) was conducted. Fisher’s Exact Test, Kruskal-Wallis rank sum test, and ordinal logistic regressions with Benjamini-Hochberg (BH) adjustment on p-values were used to assess the influence of chronic conditions on COVID-19 severity, adjusting for age and gender. (3) Results: Among 216 records, significant associations were found for stroke, chronic kidney disease, lung disease, and neurologic conditions (p<0.05). Type 1 diabetes was marginally significant (0.05<p<0.1). After adjusting for age and sex, stroke (p=0.0008, BH-adjusted p=0.0044) and chronic kidney disease (p=0.0003, BH-adjusted p=0.0033) significantly increased the risk of severe COVID-19 outcomes. (4) Conclusions: Pre-existing medical conditions should be considered in the clinical management and public health interventions for PLWH with COVID-19. Tailored strategies are essential to mitigate the higher risk of severe outcomes in PLWH with specific chronic comorbidities.

1 August 2026 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
EJElzbieta Jodlowska-Siewert
Elzbieta Jodlowska-Siewert
LLLimeng Liu
Limeng Liu
KYKaifeng Yang
Kaifeng Yang
DODenis Ostroushko
Denis Ostroushko
PLPamela Lutsey
Pamela Lutsey
FIFor The Alzheimer'S Disease Neuroimaging Initiative
For The Alzheimer'S Disease Neuroimaging Initiative
Background: Mild cognitive impairment (MCI) is an intermediate stage between normal aging and Alzheimer's disease (AD). Because there is no treatment for AD, it is vital to establish which patients are at a higher risk of disease progression, and might benefit from early intervention. Objective: This study investigates whether a score based on clusters of MRI and lipidomic variables can predict the time to moderate progression in MCI. Methods: We analyzed MRI and lipidomics data from 480 individuals with MCI (mean age 72.14 years, range 55–90 years). Moderate progression was defined as a ≥ 2.5-point increase in the Clinical Dementia Rating Scale Sum of Boxes (baseline mean CDR-SB of 1.2, range 0–10 points). Multi-source data integration and clustering methods were used to derive predictive scores. Results: The MRI-based score outperformed the lipidomics score (c-index: 0.754 versus 0.666). A 1-unit increase in the MRI score was linked to a 13% higher risk of moderate progression. Individuals in the top 25% of MRI scores had a 3-fold greater risk of decline. Conclusions: An MRI-based score offers a simple, effective tool to predict moderate MCI progression and identify high-risk individuals for AD.

20 November 2024 in COVID
Verified
Journal Article
Open access
PDF file
TATaiwo Opeyemi Aremu
Taiwo Opeyemi Aremu
KYKaifeng Yang
Kaifeng Yang
HLHan Lu
Han Lu
OOOluwatosin Esther Oluwole
Oluwatosin Esther Oluwole
KAKehinde Adeyinka
Kehinde Adeyinka
(1) Background: The Coronavirus Disease 2019 (COVID-19) pandemic has raised concerns about the impact of underlying medical conditions on the health outcomes of people living with HIV (PLWH). This study aimed to assess how pre-existing chronic medical conditions affect the health outcomes of PLWH infected with COVID-19. (2) Methods: A retrospective study using data from the Minnesota Fairview network (1 January 2020–31 December 2022) was conducted. Fisher’s exact test, the Kruskal–Wallis rank-sum test, and ordinal logistic regressions with a Benjamini–Hochberg (BH) adjustment on p-values were used to assess the influence of chronic conditions on COVID-19 severity, adjusting for age and gender. (3) Results: Among 216 records, significant associations were found for a stroke, chronic kidney disease, lung disease, and neurologic conditions (p < 0.05). Type 1 diabetes was marginally significant (0.05 < p < 0.1). After adjusting for age and sex, a stroke (p = 0.0008, BH-adjusted p = 0.0044) and chronic kidney disease (p = 0.0003, BH-adjusted p = 0.0033) significantly increased the risk of severe COVID-19 outcomes. (4) Conclusions: Pre-existing medical conditions should be considered in the clinical management and public health interventions for PLWH infected with COVID-19. Tailored strategies are essential to mitigate the higher risk of severe outcomes in PLWH with specific chronic comorbidities.